Abstracts tagged "Myositis"

Abstract Number: 0451 • ACR Convergence 2020
Prevalence, Therapy and Tumor Response in Patients with Rheumatic Immune-related Adverse Events Following Immune Checkpoint Inhibitor Therapy: A Single-Centre Analysis
Sophia Verspohl¹, Tobias Holderried¹, Charlotte Behning², Peter Brossart¹ and Valentin Schaefer³, ¹Clinic for Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ²Institute for Medical Biometrics, Informatics and Epidemiology (IMBIE), University Hospital Bonn, Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, ³Clinic of Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany
Background/Purpose: Immune checkpoint inhibitors (ICIs) have improved cancer therapy [1] by inducing a higher immune system activity and subsequent attack of tumor cells. However, this effect…
Abstract Number: 1073 • ACR Convergence 2020
Anti Melanoma Differentiation-associated Protein Gene 5 Antibody Titer Monitoring Is a Useful Indicator for Early Detection of Recurrence in Rapidly Progressive Interstitial Lung Disease Associated with Dermatomyositis
Yuji Hosono¹, Azusa Kojima², Keigo Shimura², Akira Ishii², Yuto Izumi², Kazuki Hirano², Sho Sasaki², Takayoshi Kurabayashi², Noriko Sasaki², Chiho Yamada² and Shinji Sato², ¹Tokai University School of Medicine, Kanagawa, Japan, ²Tokai University School of Medicine, Isehara, Kanagawa, Japan
Background/Purpose: Anti melanoma differentiation-associated gene 5 (MDA5) antibody (Ab) positive dermatomyositis (DM) often complicates rapidly progressive interstitial lung disease (RP-ILD), which shows fatal prognosis at…
Abstract Number: 1093 • ACR Convergence 2020
Impact of Blood Flow Restricted Strength Training on Myogenic Stem Cells and Myofiber Hypertrophy in Sporadic Inclusion Body Myositis Patients
Kasper Yde Jensen¹, Henrik Daa Schrøder², Jakob Nielsen³, Mikkel Jacobsen³, Eleanor Boyle³, Anders Nørkær Jørgensen³, Rune Dueholm Bech⁴, Per Aagaard³ and Louise Pyndt Diederichsen¹, ¹Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark, ²Odense University Hospital, Odense, Denmark, ³University of Southern Denmark - Odense, Odense, Denmark, ⁴Zealand University Hospital, Copenhagen, Denmark
Background/Purpose: Sporadic inclusion body myositis (sIBM) is clinically characterised by marked progressive muscle weakness and impaired physical function. Physical training has become an area of…
Abstract Number: 082 • 2020 Pediatric Rheumatology Symposium
Anti-Mitochondrial Autoantibodies Are Associated with Dysphagia in Juvenile and Adult Myositis, and with Persistent Weakness and Cardiomyopathy in Adult Myositis
Sara Sabbagh¹, Iago Pinal-Fernandez ², Maria Casal-Dominguez ³, Frederick W. Miller ⁴, Lisa G. Rider ⁵, Andrew Mammen ³ and Lisa Christopher-Stine ⁶, ¹NIH/NIAMS, Bethesda, ²National Institutes of Health, Bethesda, ³NIH, Bethesda, ⁴Bethesda, ⁵NIEHS, NIH, Garrett Park, ⁶Johns Hopkins University, Baltimore
Background/Purpose: We analyzed the prevalence of anti-mitochondrial autoantibodies (AMA) in both juvenile-(JM) and adult-onset myositis cohorts and investigated phenotype differences between juvenile and adult myositis…
Abstract Number: 389 • 2019 ACR/ARP Annual Meeting
ACR/EULAR Criteria for Myositis and Systemic Sclerosis Lack Sensitivity for Scleromyositis
Alain Meyer¹, Valérie Leclair ², Océane Landon-Cardinal ³, Benjamin Ellezam ⁴, Julie D'Aoust ⁵, Margherita Giannini ⁶, Bernard Geny ⁶, Laurent Arnaud ⁷, Jacques-Eric Gottenberg ⁸, Jean Sibilia ⁹, Minoru Satoh ¹⁰, Marvin Fritzler ¹¹, Yves Troyanov ¹² and Marie Hudson ¹³, ¹Centre de Reference des Maladies Autoimmunes Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ²Division of Rheumatology, Department of Medicine, Jewish General Hospital; Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Montreal, QC, Canada, ³Centre Hospitalier de l'Université de Montréal, Montréal, Canada, ⁴Department of Pathology, Centre Hospitalier Universitaire Sainte-Justine, Montréal, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶CHU de Strasbourg, Strasbourg, France, ⁷Service de Rhumatologie, Centre National de Référence des Maladies Autoimmunes Systemiques Rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, France, Strasbourg, France, ⁸Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁹CHU Strasbourg, Strasbourg, France, ¹⁰Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹²Division of Rheumatology, Department of Medicine, Hôpital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ¹³Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada
Background/Purpose: Autoimmune myositis consists of a group of diseases with heterogeneous muscular and systemic manifestations. Prognosis also varies widely across the spectrum. Thus, myositis subgroups…
Abstract Number: 399 • 2019 ACR/ARP Annual Meeting
Seasonal and Temporal Analyses of Disease Onset and Diagnosis in Myositis Autoantibody Phenotypes in Juvenile Dermatomyositis (JDM)
Gulnara Mamyrova¹, Min Shi ², Ira N. Targoff ³, Rodolfo V. Curiel ¹, Frederick W. Miller ⁴ and Lisa G. Rider ⁵, ¹George Washington University, School of Medicine and Health Sciences, Washington, DC, ²Biostatistics&Computational Biology Branch, NIEHS, NIH, Research Triangle Park, NC, ³Arthritis Immunology Section, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴NIEHS, NIH, Bethesda, MD, ⁵Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Bethesda, MD
Background/Purpose: Published studies suggest seasonal occurrence of disease onset and disease activity in patients with adult idiopathic inflammatory myopathies (IIM).Our objective was to evaluate seasonal…
Abstract Number: 404 • 2019 ACR/ARP Annual Meeting
Autoantibody Profiles Delineate Three Distinct Subsets of Scleromyositis
Julie D'Aoust¹, Valérie Leclair ², Geneviève Gyger ³, Alain Meyer ⁴, Marvin Fritzler ⁵, Océane Landon-Cardinal ⁶, Erin O'Ferrall ⁷, Jason Karamchandani ⁷, Benjamin Ellezam ⁸, Rami Massie ⁷, Minoru Satoh ⁹, Yves Troyanov ¹⁰ and Marie Hudson ¹¹, ¹McGill University, Montreal, QC, Canada, ²Division of Rheumatology, Department of Medicine, Jewish General Hospital; Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Montreal, QC, Canada, ³Division of Rheumatology, Department of Medicine, Jewish General Hospital, Montreal, QC, Canada, ⁴Centre de Reference des Maladies Autoimmunes Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁵Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁶Division of Rheumatology, Centre hospitalier de l'Université de Montréal; Department of Medicine, Université de Montréal, Montreal, QC, Canada, ⁷Montreal Neurological Institute, Montreal, QC, Canada, ⁸Centre hospitalier universitaire Sainte-Justine, Montreal, QC, Canada, ⁹Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁰Division of Rheumatology, Department of Medicine, Hôpital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ¹¹Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada
Background/Purpose: Myopathy is an important cause of morbidity in systemic sclerosis (SSc). Nevertheless, scleromyositis remains incompletely characterized owing at least in part to its clinical…
Abstract Number: 881 • 2019 ACR/ARP Annual Meeting
Auto-antibodies Targeting Components of Sarcolemma Repair: A Pathogenic Mechanism in Human Inflammatory Myopathies
Kevin McElhanon¹, Ana Capati ², Nicholas Young ³, Brian Paleo ², Eric Beck ², Zarife Sahenk ⁴, Rohit Aggarwal ⁵, Chester Oddis ⁵, Noah Weisleder ¹ and Wael Jarjour ⁶, ¹Dorothy M. Davis Heart and Lung Research Institute & Dept. of Physiology & Cell Biology, The Ohio State University Wexner Medical Center, Columbus, OH, ²The Ohio State University Wexner Medical Center, Columbus, OH, ³The Ohio State University Wexner Medical Center, Division of Immunology and Rheumatology, Columbus, OH, ⁴Nationwide Children's Hospital, Columbus, OH, ⁵University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶Ohio State College of Medicine, Columbus, OH
Background/Purpose: Idiopathic inflammatory myopathies (IIM) represent a group of disorders causing chronic inflammation and significant damage to skeletal muscle due to an unchecked autoimmune response. …
Abstract Number: 1286 • 2019 ACR/ARP Annual Meeting
Patients with Anti-tRNA Synthetase Syndrome Are More Likely to Present to Pulmonary Clinic and Have a Higher Prevalence and Severity of Lung Disease Than Patients with Other Types of Myositis or Systemic Sclerosis
Bret Sohn¹, Erin Wilfong ¹ and Leslie Crofford ¹, ¹Vanderbilt University, Nashville
Background/Purpose: Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in idiopathic inflammatory myopathies (IIM) as well as systemic sclerosis (SSc). The…
Abstract Number: 1288 • 2019 ACR/ARP Annual Meeting
Line Blot Immunoassay in Inflammatory Myopathies: Diagnostic Accuracy and Factors Predicting Positive Results in Routine Clinical Practice
Fergus To¹, Clara Ventín Rodríguez ², Shuayb Elkhalifa ³, James Lilleker ⁴ and Hector Chinoy ⁴, ¹University of British Columbia, Vancouver, Canada, ²Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ³(3) Department of Immunology, Salford Royal NHS Foundation, Salford, United Kingdom, ⁴University of Manchester, Manchester, United Kingdom
Background/Purpose: To evaluate the real-world accuracy of a line blot immunoassay (LIA) for myositis-specific (MSA) and myositis-associated (MSA) autoantibody testing in patients at a tertiary…
Abstract Number: 1291 • 2019 ACR/ARP Annual Meeting
Semi-Quantitative and Quantitative Evaluation of Magnetic Resonance Imaging in Patients with Idiopathic Inflammatory Myopathies – a Subanalysis of the Prometheus Study
Katerina Kubinova¹ and Jiří Vencovský ², ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, ²Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic
Background/Purpose: Prometheus study was a prospective, randomized, assessor-blind multicenter trial, comparing the efficacy and safety of the glucocorticoid (GC) monotherapy versus combination therapy with methotrexate…
Abstract Number: 1292 • 2019 ACR/ARP Annual Meeting
Abnormal High Density Lipoprotein Particle Size and Number in Idiopathic Inflammatory Myopathies
Sangmee Bae¹, Ilana Golub ², Ani Shahbazian ³, Jennifer Wang ³ and Christina Charles-Schoeman ⁴, ¹UCLA, Los Angeles, CA, ²UCLA, Los Angeles, ³UCLA Medical Center, Los Angeles, ⁴University of California, Los Angeles, CA
Background/Purpose: Vascular inflammation and damage are implicated in the pathogenesis of idiopathic inflammatory myopathies (IIM), particularly dermatomyositis (DM). High and low density lipoprotein (HDL, LDL)…
Abstract Number: 1294 • 2019 ACR/ARP Annual Meeting
Alterations in Activin A-Myostatin-Follistatin System Associate with Disease Activity in Inflammatory Myopathies
Lucia Vernerová¹, Veronika Horvathová ², Tereza Kropáčková ³, Martina Vokurková ², Martin Klein ¹, Sabina Oreska ⁴, Katerina Kubinova ⁵, Herman Mann ⁴, Maja Spiritovic ⁶, Hana Storkanova ¹, Olga Kryštůfková ¹, Michal Tomcik ⁴, Jozef Ukropec ⁷, Barbara Ukropcová ⁷ and Jiří Vencovský ⁴, ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Institute of Rheumatology, Prague, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁵Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, ⁶Faculty of Physical Education and Sport, Department of Physiotherapy, Charles University, Prague, Czech Republic, Prague 2, Hlavni mesto Praha, Czech Republic, ⁷Institute of Experimental Endocrinology, Biomedical center, Slovak Academy of Sciences, Bratislava, Slovakia
Background/Purpose: The aim of this study was to investigate myokines involved in muscle atrophy such as myostatin, follistatin and activin A, in idiopathic inflammatory myopathies…
Abstract Number: 2245 • 2019 ACR/ARP Annual Meeting
Polymyositis (PM) and Dermatomyositis (DM) Symptom Flares and Associated Impact from the Patient Perspective
Lisa Christopher-Stine¹, William Kelly ², George Wan ³, Linda Kobert ⁴ and Michael Reed ⁵, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins Myositis Center, Baltimore, MD, ³Mallinckrodt Pharmaceuticals, Bedminster, NJ, ⁴The Myositis Association, Alexandria, VA, ⁵Vedanta Research, Chapel Hill, NC
Background/Purpose: Flare activity or worsening symptoms are not well defined for myositis. This analysis characterizes PM and DM flares from the patient perspective and reports…
Abstract Number: 2840 • 2019 ACR/ARP Annual Meeting
Reliability, Validity and Responsiveness of PROMIS PF-20 in Patients with Inflammatory Myopathy
Didem Saygin¹, Chester Oddis ¹, Nicole Neiman ¹, Diane Koontz ¹, Siamak Moghadam-Kia ¹ and Rohit Aggarwal ¹, ¹University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of rare, debilitating systemic diseases characterized by proximal muscle weakness, which limit activities of daily living and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].